We are submitting herewith the Annual Report of the Company for the financial year 2025-26.

Date: September 03, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Dear Sir/Madam, Sub.: Notice of the Nineth (9th) Annual General Meeting and Annual Report for Financial Year 2025-26 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we are submitting herewith the Notice convening the Nineth (9th) Annual General Meeting (“AGM”) and Annual Report including the Business Responsibility and Sustainability Report of the Company for the Financial Year 2025-26. The Annual Report will be sent through electronic mode to the members of the Company whose email addresses are registered with the Company / Depository Participants. The AGM is scheduled to be held on Friday, September 25, 2026 at 11:30 A.M. (IST) through Video Conferencing (“VC”)/ Other Audio-Visual Means (“OAVM”). The important information related to AGM are as follows: Friday, September 25, 2026, at 11:30 A.M. (IST) Details of AGM through Video Conference / Other Audio Visual Means. Cut-off date to determine the list of Friday, September 18, 2026 members entitled for e-voting Remote e-voting start time and date From Tuesday, September 22, 2026, 09:00 A.M. (IST) (prior to the AGM) onwards Remote e-voting end time and date Till Thursday, September 24, 2026, 05:00 P.M. (IST) (prior to the AGM) Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Further, in accordance with Regulation 36(1)(b) of the SEBI Listing Regulations, the Company has sent separate communication to Members whose email addresses are not registered with the Company / Depository Participants, providing a web link to access the Annual Report on the Company’s website. The aforesaid documents are also available on Company’s website at https://senorespharma.com/reports1/. You are requested to take the same on record. Thanking you. For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary and Compliance Officer ICSI Membership No.: A34516 Encl.: As mentioned above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Positioned for Next Leap Senores Pharmaceuticals Limited Annual Report 2025-26 Across the Pages Positioned for the Next Leap Corporate 1-40 Overview We have always believed that building a scaled We are not building for one product cycle or pharmaceutical business requires more than one market. We are building capabilities that a strong product pipeline. It requires the right can support multiple growth engines across 2 About the Company Scan this QR Code to access capabilities, manufacturing infrastructure and Regulated Markets, Emerging Markets and 8 Management Message the Investor Relations page access to markets. Over the past few years, we Branded Generics. have been deliberately building each of these 12 Business Segments As we enter the next phase, our opportunity is Disclaimer pieces, both organically and through strategic 16 Mergers and Acquisitions to bring these capabilities together, scale the acquisitions and partnerships. This document contains statements about assets we have added and continue to pursue 18 Strengths expected future events and financials of Senores 2025-26 marked a significant step forward opportunities that complement our existing Pharmaceuticals Limited (‘The Company’), which 28 Manufacturing Facilities are ‘forward-looking’. By their nature, forward- in that journey. We delivered strong growth strengths. With a growing product pipeline and 32 Financials looking statements require the Company to make and profitability while materially expanding a platform that is becoming broader and more assumptions and are subject to inherent risks our product portfolio and strengthening our integrated, we believe we are positioned to take 34 Strategies and uncertainties. There is a significant risk that presence across the pharmaceutical value chain. a significantly larger step forward. the assumptions, predictions, and other forward- 38 ESG Commitment At the same time, our inorganic initiatives have looking statements may not prove to be accurate. helped us add manufacturing capabilities, 40 Corporate Information Readers are cautioned not to place undue reliance on forward-looking statements as several factors deepen our US market access and strengthen We have built the could cause assumptions, actual future results and our ability to participate directly in attractive events to differ materially from those expressed segments of the market. platform. Now, we are in the forward-looking statements. Accordingly, ready to accelerate its this document is subject to the disclaimer and This combination of organic execution and Statutory 41-120 qualified in its entirety by the assumptions, targeted M&A gives us a broader platform from potential. Reports qualifications and risk factors referred to in the which to grow. Management Discussion and Analysis section of this Annual Report. 41 Notice 61 Director’s Report Investor Information 81 Corporate Governance Report Market Capitalization `3,490.40 Cr 111 Management Discussion and Analysis (as of March 31, 2026) CIN L24290GJ2017PLC100263 BSE Code 544319 Financial NSE Symbol SENORES 121-259 Statements AGM Date September 25, 2026 Video Conferencing (‘VC’) AGM Mode 122 Standalone /Other Audio-Visual Means 189 Consolidated About the Company Expanding the Possibilities of Healthcare Mission We are a research-driven, Senores Pharmaceuticals is on formulation-focused a mission to bridge the gap pharmaceutical company between affordable healthcare engaged in the identification, and accessibility of niche development, manufacturing, category products. and commercialization of niche, specialty, and complex pharmaceutical products. We primarily serve Regulated Markets, including the US, Canada, and the United Kingdom, across a range of therapeutic areas and dosage forms. Vision Our business is anchored in identifying At Senores Pharmaceuticals, we envision underpenetrated and differentiated to become a global market leader in product opportunities and translating niche category products developed these opportunities into commercially with continuous improvements viable pharmaceutical products. in innovation, production, and We leverage our capabilities across manufacturing verticals. research, formulation development, regulatory affairs, and manufacturing to develop products that address evolving healthcare needs while meeting stringent quality and regulatory requirements. Building on these capabilities, we are developing a differentiated portfolio of specialty and complex pharmaceutical products across select therapeutic areas. Our focus on niche opportunities, combined with our formulation and manufacturing capabilities, enables us to participate in segments with specialized requirements and supports our growth across global Regulated Markets. stnemetatS laicnaniF stropeR yrotutatS weivrevO etaroproC 62-5202 tropeR launnA detimiL slacituecamrahP seroneS Corporate Structure Global Certifications USFDA Health Canada UK MHRA Group holding company based in India Houses Domestic Branded Generics business & API business DEA WHO-GMP ISO 9001:2015 Ratnatris Senores Pharmaceuticals Enters U.S. Federal Pharmaceuticals Inc. Pvt Ltd. Market via Strategic Marketing cum ANDA Caters [Showing first 8,000 characters — download PDF for full document]